Cell-line experimentation indeed validated that PRDM1 knockdown in human stomach cancer cell line SNU-1 decreased BRD4 expression, proliferation, and sensitivity to BET inhibitor. The gene discussed is PRDM1; the disease is gastric neoplasm.